What follows is neither hagiography nor hit piece. It’s an accounting of Sinclair’s protocol, the scientific framework underneath it, the evidence quality behind each piece, and the honest gap between what the research shows and what personal testimony implies. Sinclair is a legitimate scientist doing legitimate science. He is also a man who self-experiments in public and holds financial stakes in parts of the space he promotes. Both things are true. A clear-eyed read holds both at once.
The Information Theory of Aging: Sinclair’s Core Framework
Sinclair’s theoretical contribution centers on what he calls the information theory of aging. Conventional wisdom says aging comes from accumulated DNA mutations — genetic typos piling up across decades until cellular function breaks down. Sinclair argues that’s an incomplete explanation. Centenarians carry roughly as many DNA mutations as people who die of cancer at 70. Mutation count alone doesn’t explain the longevity gap.
His alternative: aging is primarily an information problem in the epigenome, not the genome. The DNA sequence — the genome — behaves like a hard drive, relatively intact even in old age. The epigenome — methylation patterns, histone modifications, chromatin structure, the machinery that decides which genes actually get expressed — behaves like the software. With age the software corrupts. Marks that should silence certain genes fail. Marks that should switch other genes on fail too. Cells lose their identity. A liver cell that should act like a liver cell starts expressing genes it has no business expressing, or drops genes it needs.
The survival circuit hypothesis extends the idea: Sinclair proposes a conserved “survival circuit” — SIRT1 and the other sirtuins, primarily — that evolved to respond to adversity signals (hunger, cold, low oxygen, DNA damage) by redirecting resources toward survival and away from reproduction. The sirtuins do double duty, both stress responders and epigenetic maintenance crew. Called away too often to fight cellular fires — DNA repair, stress response — the epigenome slowly corrupts from neglect. Aging, in this framing, is the accumulated corruption from a survival circuit that can’t be in two places at once.
The framework generates testable predictions, some already tested. The landmark demonstration: reprogramming cells with Yamanaka factors restores epigenetic youth — the epigenetic program, it turns out, can be reset toward something younger even in aged cells. Whether that can be done safely in a whole organism, selectively enough to avoid tipping into cancer, is the open question everything else hinges on.
The question isn’t whether we can reverse epigenetic aging in cells. We can. The question is whether we can do it selectively enough, in the right tissues, without unacceptable risks. That’s what separates a Nobel Prize theory from a clinical therapy.
The Sinclair Protocol, Piece by Piece
Sinclair’s personal protocol has shifted over years, described across podcast appearances, the book, and social media. As of 2026, the current iteration, with an evidence read attached to each piece:
NMN (Nicotinamide Mononucleotide) — 1,000 mg daily, morning. NMN is an NAD+ precursor — it raises intracellular NAD+, which declines with age, and NAD+ is required for sirtuin activity, the survival circuit’s fuel. Sinclair switched from NR (nicotinamide riboside, another NAD+ precursor) to NMN based on his own read of superior efficacy. Evidence: preclinical data is strong — NMN extends healthspan in mice. Human data is accumulating: several clinical trials show NMN raises blood NAD+, improves muscle insulin sensitivity in older women, and shows assorted metabolic benefits in small trials. Not yet confirmed to extend human lifespan. Sinclair takes it with yogurt — fat and protein may aid absorption. He co-founded a company (Metro International Biotech) developing pharmaceutical NMN, which is a disclosed but notable financial interest.
Resveratrol — 1,000 mg daily, with yogurt/fat. Resveratrol is a red-wine polyphenol that activates SIRT1, the primary sirtuin in Sinclair’s framework. This was the centerpiece of his early public career — the 2003 Nature paper linking resveratrol to sirtuin activation made global headlines. Since then the trajectory has been mixed. GSK bought Sirtris Pharmaceuticals, which Sinclair co-founded on the resveratrol premise, for $720 million in 2008, then shut it down after clinical failures. Trials like PREDIMED suggest dietary polyphenol-rich patterns benefit cardiovascular health, but isolated high-dose resveratrol hasn’t shown the same consistency. The clinical trial record for supplemental resveratrol is disappointing next to the preclinical hype. The financial history adds a real conflict-of-interest consideration.
Metformin — 500-1,000 mg daily (prescription). Sinclair takes metformin as an AMPK activator, chasing its multiple anti-aging signals — mTOR suppression, FOXO activation, mitochondrial effects. He’s said he pauses it on hard training days, since metformin may blunt certain exercise adaptations, VO2 max gains in particular. Evidence: solid observational data for longevity effects in diabetics and pre-diabetics. The TAME trial will bring cleaner data for non-diabetics. The exercise interference is real, shown in randomized trials reducing aerobic adaptation gains — a genuine trade-off between longevity pharmacology and optimal fitness adaptation. Requires physician prescription; not for self-directed use.
Vitamin D3 + K2 — Sinclair takes these together, the standard pairing for proper vitamin D metabolism. Evidence: strong for correcting deficiency, modest beyond 50 ng/mL.
Low-dose aspirin (81 mg) — was part of the stack historically; Sinclair has voiced more ambivalence lately, following updated meta-analyses showing less net benefit and higher bleeding risk in primary prevention.
Quercetin and fisetin — used intermittently as senolytics.
Spermidine — for autophagy induction. 1-2 mg daily from wheat germ extract or supplement. Evidence: observational data linking spermidine intake to lower all-cause mortality. The mechanism, autophagy induction, is well-characterized. Human interventional trials remain limited.
The Diet: Time-Restricted, Plant-Forward
Sinclair’s eating pattern gets less attention than the supplement stack, arguably despite mattering just as much. Primarily plant-based, time-restricted — and it invokes several longevity pathways at once.
Time-restricted eating — eating in a compressed window, typically 6-8 hours, fasting the remaining 16-18 — activates AMPK, suppresses mTOR, upregulates autophagy. The same pathways caloric restriction hits in animal longevity studies. Duration and consistency of the fasting window matter more than which specific hours are chosen. Sinclair typically skips breakfast, eats first around lunch.
Plant-forward, not strictly vegan, eating leans on polyphenol-rich vegetables, legumes, whole grains. Polyphenols trigger xenohormetic pathways — mild-stress signals plants generate under environmental pressure, which happen to overlap with the longevity pathways activated in animals that consume them. Sinclair’s xenohormesis hypothesis: eating plants under stress — drought, UV exposure, disease — passes along their protective signaling to whoever eats them. Whether the mechanism is mechanistically precise is debated. The epidemiological case for polyphenol-rich diets and longevity is strong regardless.
Cold exposure and high-intensity exercise round out the deliberate stressors in Sinclair’s routine. Both are mild hormetic triggers, hitting the same survival circuit pathways caloric restriction activates. The framework stays consistent throughout: adversity signals that evolved to promote survival also appear to promote longevity when invoked through lifestyle rather than actual life-threatening events.
Where the Framework Gets Challenged
The sharpest pushback comes from researchers arguing that the sirtuin/epigenetic information theory of aging, compelling as it reads, remains a hypothesis rather than a proven mechanism. Charles Brenner (University of California Irvine), a prominent NAD+ researcher and co-discoverer of NR as an NAD+ precursor, has been openly critical of what he calls Sinclair’s overstatement of the evidence — for NMN specifically, and sirtuin-based longevity more broadly. Brenner’s case: sirtuin activation is context-dependent, the in vivo evidence for pure SIRT1 activation extending mammalian lifespan is thin, and the NAD+ precursor market has significantly outrun what the evidence supports.
The resveratrol credibility gap hasn’t closed. The clinical failures after all that early excitement — GSK abandoning the Sirtris program among them — suggest the preclinical-to-human translation was less direct than the early science implied. Sinclair has defended resveratrol’s relevance while acknowledging the translation problems. Fair reading: isolated resveratrol supplementation probably does something. The dramatic effects seen in early yeast and mouse models simply haven’t shown up as clearly in human clinical endpoints.
Protein restriction is another point of friction. Sinclair runs low on animal protein partly because high protein intake activates mTOR, which suppresses the longevity pathways he’s chasing. But the evidence for mTOR suppression as a human longevity strategy, at the cost of lower protein intake, trades off against sarcopenia risk — particularly in older adults, where muscle mass and strength are among the strongest predictors of longevity in the human data. Optimizing for muscle preservation and optimizing for mTOR suppression can pull in opposite directions, especially past 60.
The honest assessment of Sinclair’s work: he’s moved a genuine scientific conversation into public awareness with tremendous effect. The underlying biology is real. The clinical translation of specific supplement interventions is less proven than his public advocacy suggests. Both are true simultaneously.
What to Take From It If You’re Not David Sinclair
The full Sinclair protocol involves prescription medications, supplements with real financial interests attached, and lifestyle commitments demanding actual understanding of the underlying science to run safely. Here’s the evidence-solid slice general enough to apply broadly:
- Time-restricted eating (16:8 window) — strong mechanistic and human metabolic evidence, low risk, free
- Plant-forward diet with diverse polyphenol-rich foods — strong epidemiological backing
- High-intensity exercise combined with strength training — the single most evidence-backed longevity intervention there is
- Vitamin D3 + K2 to optimal levels — well established
- NAD+ precursors (NMN or NR) — reasonable for adults over 40, given the current evidence trajectory; doesn’t need a Harvard lab to justify
- Quarterly senolytic cycles (fisetin/quercetin) — reasonable risk-benefit given the evidence available
- Cold exposure (cold showers, cold plunge) — low risk, multiple mechanistic benefits
Metformin belongs under physician guidance only. Resveratrol has a weaker evidence base than Sinclair’s public advocacy implies — the polyphenol-rich food approach is better supported outright. The most valuable thing Sinclair has actually contributed isn’t any specific supplement stack. It’s the reframe: aging as a modifiable biological process rather than an inevitable decline. That idea carries more weight than any single compound on the list.
FAQ: David Sinclair Protocol
Q: NMN or NR — which is better?
Both raise blood NAD+. Head-to-head human trials are limited. NMN is what Sinclair currently favors; NR has the longer human trial track record, developed originally by Charles Brenner’s group. Either works fine for most people. NR is typically cheaper. NMN may have a slight uptake advantage in some tissues thanks to the SLCO2B1 transporter characterized in recent years. Budget allowing, NMN; budget-conscious, NR is a reasonable substitute. The human trials have run on much the same amounts either way.
Q: Does the conflict of interest mean the work should be dismissed?
Financial interests should raise scrutiny, not trigger dismissal. Sinclair has been transparent about his commercial ties. The real test: does the science hold up independent of who’s promoting it? Mostly, yes — the foundational science (sirtuin biology, NAD+ metabolism, epigenetic aging) is genuine and has been reproduced by independent labs. Where the evidence thins out, and where financial interest most distorts the messaging, is the clinical translation of specific supplements. Extra rigor there. Less needed on the foundational biology.
Q: Does Sinclair actually look younger than his age?
He publishes epigenetic age results claiming meaningful biological age deceleration, and he does appear physically younger than plenty of 55-year-olds. Suggestive, not scientific evidence for the protocol’s efficacy — the confounders (genetics, the Hawthorne effect of constant self-monitoring, the money and time available for health optimization) are enormous. The absence of controlled evidence for his specific personal protocol remains the core limitation.
Partial Reprogramming: Sinclair’s Next Act
The theory: Yamanaka factor expression reprograms the epigenome toward a younger state, restoring the methylation patterns of youthful cells. In Sinclair’s lab, a short pulse of partial reprogramming — not continuous — restored vision in aged mice by reversing epigenetic aging in retinal ganglion cells. The neurons regenerated after injury, something not seen in aged, untreated animals. Later work showed systemic rejuvenation effects across multiple tissue types in aged mice.
The human translation problem is substantial. Yamanaka factors include c-Myc, a potent oncogene. Partial reprogramming walks a careful line — controlled expression, threading between epigenetic rejuvenation and tumor induction. Several biotech companies — Turn Bio, Retro Biosciences (backed in part by OpenAI’s Sam Altman), Altos Labs (backed by Jeff Bezos and others, staffed with multiple Nobel laureates) — are racing toward clinical applications. Altos specifically focuses on cellular reprogramming as a longevity therapy, with Sinclair as a scientific advisor.
Timeline to human application: most researchers in the field put it at 10-15 years to clinical therapy for partial reprogramming, assuming the cancer-risk safety profile can be managed. First applications will likely target specific diseases — optic nerve injury, age-related vision loss, cardiac regeneration — rather than systemic anti-aging. If it works, it represents a categorical leap past anything currently available: not slowing aging, but actually resetting the epigenetic clock in target tissue.
NAD+ Biology: The Full Evidence Picture
NAD+ is arguably the most important molecule in the entire Sinclair framework — sirtuin fuel, PARP enzyme cofactor, the metabolic regulator whose age-related decline tracks with nearly every hallmark of aging. Understanding the full evidence picture helps calibrate whether and how much to supplement.
NAD+ in muscle tissue drops roughly 50% between age 40 and 70. Multiple factors drive it: decreased synthesis (declining NMN/NR dietary intake, reduced tryptophan-to-NAD pathway efficiency), increased consumption (CD38 upregulation with age and senescent cell accumulation), reduced recycling (NAMPT enzyme decline). The functional fallout — reduced sirtuin activity, impaired DNA repair, mitochondrial dysfunction — connects mechanistically to the aging phenotype cleanly.
The human supplementation evidence for NMN specifically: a 2021 Phase II randomized trial (Igarashi et al.) in healthy older men (65-80) showed 250 mg NMN daily for 12 weeks improved muscle insulin sensitivity, physical performance, and blood NAD+ levels. A 2022 trial in pre-diabetic women (60-70) showed improved muscle insulin sensitivity and gene expression shifts in muscle tissue. A 2023 meta-analysis of NMN and NR trials found both reliably raise blood NAD+, but concluded the downstream health effects need larger, longer trials before anything definitive can be said.
The honest summary: NAD+ precursors reliably raise blood NAD+. They improve metabolic function in older adults and in people with metabolic dysfunction. Whether they extend lifespan or meaningfully slow aging in already-healthy middle-aged adults isn’t yet confirmed at the level an FDA approval would demand. The risk-benefit is favorable enough that many longevity researchers, Sinclair’s critics included, take them anyway. Morning, with food, at the amounts the trials have used — that is the practical takeaway from the research context.
A Graded Sinclair-Inspired Protocol
Not everyone can run the full Sinclair protocol — financially, medically, logistically. A graded approach by commitment level:
- Foundation level (free to $50/month): Time-restricted eating (16:8), plant-forward diet, daily aerobic exercise plus 2x/week resistance training, consistent sleep schedule, cold exposure, no smoking.
- Supplement level ($50-150/month): Add vitamin D3 + K2 (optimized to 60-80 ng/mL via testing), omega-3 EPA/DHA, magnesium glycinate, NMN or NR, quarterly fisetin/quercetin senolytic cycles.
- Testing level (add $300-500/year): Annual blood panel (ApoB, hs-CRP, HbA1c, homocysteine, DHEAS, testosterone, vitamin D), epigenetic age test (TruDiagnostic), and a 2-week CGM session annually.
- Advanced level (with physician guidance, $200-400/month): Metformin evaluation if appropriate, rapamycin consultation if indicated, prescription NAD+ therapy, comprehensive hormonal optimization, therapeutic-dose NAD+ infusions.
The returns curve is steep. Foundation level likely captures 60% of the available benefit. Supplement level adds another 15-20%. Testing level adds accountability and personalization. Advanced level adds 5-10% incremental benefit at substantially higher complexity and cost. Where to invest depends on resources, risk tolerance, and how central longevity optimization is to the rest of life.
How to Read the Sinclair Debate
Separate mechanism from clinical translation. Sirtuin biology is real and well-supported. Jumping from that to “take this specific supplement at this specific dose and live longer” is a significant inferential leap. Sinclair is more careful about that distinction in academic writing than in popular communication. Hold the mechanism firmly. Hold the specific commercial recommendation more loosely.
Financial interests don’t invalidate science, but they shift the prior. When a scientist co-founds a company around a research area, then publicly advocates for that area’s interventions, the odds their public communication runs more optimistic than the evidence strictly supports goes up. Doesn’t mean they’re wrong. Means independent replication should carry more weight than their own group’s findings.
The n=1 self-experiment doesn’t generalize. Sinclair’s personal results are data. They’re not evidence about what a different body will do on his protocol. Self-reported biological age improvements from someone with strong financial and reputational incentive to show improvement carry limited epistemic weight as clinical evidence.
The counterfactual is hidden. Sinclair is a physically healthy, intellectually engaged, economically secure Harvard professor with a rich social network and deep purpose in his work. Those factors alone — independent of any supplement — are among the most powerful longevity predictors in the research literature. Crediting his favorable aging trajectory to the supplement stack specifically, rather than to the life conditions that would support exceptional aging regardless, is a significant confound.
The most valuable thing Sinclair has contributed to longevity science isn’t any compound on his protocol. It’s the reframe: aging is not simply inevitable. It’s a biological process with modifiable inputs. That idea, more than any supplement, changes what’s possible.
The Xenohormesis Hypothesis, in Depth
One of the more intellectually distinctive pieces of Sinclair’s framework is the xenohormesis hypothesis — a mechanistic account of why eating plants, particularly stressed plants, might activate longevity pathways in whoever eats them. Understanding it helps evaluate the dietary recommendations that flow from it.
Xenohormesis (xeno, “foreign”; hormesis, “beneficial stress response”) proposes that plants under adversity — drought, UV radiation, pathogen attack, temperature stress — produce signaling molecules (polyphenols, flavonoids, alkaloids) that function as internal warning signals within the plant’s own stress response. Animals eating those stressed plants absorb the same signaling molecules, which happen to activate overlapping stress pathways in the consumer. The body reads the plant’s distress signal as its own environmental adversity signal, firing the same survival circuit — sirtuins, AMPK, FOXO proteins — that food scarcity or physical stress would trigger directly.
The hypothesis produces a provocative dietary recommendation: eat diverse, colorful, organic produce grown under challenging conditions. Conventional produce raised in optimized, low-stress agricultural settings may carry lower polyphenol content — less stress, less polyphenol production — than organic produce from a less pampered environment. Wild plants, foraged foods, produce grown without heavy irrigation and pesticide use would theoretically run higher in xenohormetic compounds. It’s the scientific rationale behind a recommendation that sounds backwards from a purely nutritional standpoint: slightly stressed, diverse, imperfect-looking produce may carry more longevity signaling than large, blemish-free conventional produce.
How well-supported is any of this in human evidence? The epidemiological case is strong — polyphenol-rich dietary patterns (Mediterranean, traditional Asian, indigenous diets with diverse plant foods) consistently track with longer lifespan and lower disease rates. The specific mechanism, xenohormetic signaling, is less directly proven than the dietary pattern’s benefit. What’s clear regardless: polyphenol-rich, diverse plant foods benefit cardiovascular health, metabolic health, and likely longevity through multiple overlapping mechanisms, whether or not xenohormesis turns out to be the primary driver.
Purpose, Stress, and Psychological Longevity
One dimension of Sinclair’s personal routine gets less attention than the supplements: his psychological and social approach — the factors that the non-biological longevity literature flags as among the most powerful lifespan predictors there are. A complete picture of what’s actually driving his favorable aging trajectory requires accounting for it.
Sinclair speaks often about purpose — having a compelling reason to live beyond mere self-preservation. His aging research, which he frames as a genuine mission to eliminate age-related suffering, provides a deep source of meaning and direction. The research on purpose and longevity is substantial: Boyle et al. (2009, Rush University) found a strong sense of purpose associated with a 2.4-fold reduction in Alzheimer’s risk and significantly lower all-cause mortality over 5 years. Multiple subsequent studies confirm purpose as an independent longevity predictor, separate from physical health behaviors.
Sinclair also describes managing his stress load deliberately — structuring work to maximize what’s meaningful and minimize what drains him, keeping his research intellectually engaging as a steady source of cognitive activation, surrounding himself with a network of colleagues who share his interests. Chronic psychological stress is one of the most powerful accelerants of biological aging — it elevates cortisol, activates the HPA axis, suppresses immune function, shortens telomeres, accelerates epigenetic aging. Someone who genuinely loves the work, keeps a rich social network built around shared purpose, and stays intellectually stimulated carries a longevity advantage no supplement stack replicates.
This may be the most important hidden variable in any assessment of Sinclair’s favorable aging markers: his life is structured around exactly the variables the non-supplementation longevity literature flags as the most powerful determinants. The supplements may contribute incrementally. Purpose, intellectual engagement, social connection, and the absence of chronic psychological stress may be contributing as much or more — and they happen to be the elements that are simultaneously the most important and the least commercially interesting to talk about.
The most powerful longevity interventions may not be the ones you can buy. They may be the ones you build: purpose, social connection, intellectual engagement, and a life structured around meaning rather than merely against death.
Evaluating New Longevity Research: Lessons From the Sinclair Case
Sinclair’s public career in longevity science offers a useful case study in critically evaluating emerging research claims — a skill that applies across the entire longevity space, not just to any single researcher’s work. The pattern here — exciting early findings, commercial interest, translation challenges, ongoing revision — repeats itself across nearly every major longevity intervention currently in public discourse.
Step 1: Separate mechanism from clinical evidence. Every supplement, drug, or lifestyle intervention in the longevity space carries a proposed mechanism. Mechanisms matter — they explain why something might work. But mechanism isn’t evidence that it works at clinically meaningful magnitude in the relevant human population. Resveratrol activates SIRT1 in yeast. That’s mechanism. Whether oral resveratrol at consumer doses activates SIRT1 enough in human tissue to produce longevity effects is a separate, harder question. Hold mechanistic excitement loosely until clinical translation shows up.
Step 2: Evaluate the study design and population. Mouse longevity studies are informative but not predictive of human effects — the translation rate from mouse models to human clinical benefit is famously poor across all of medicine, not just longevity. Human studies vary enormously in quality: n=1 testimonials are close to worthless; case series marginally better; randomized controlled trials with adequate follow-up and pre-registered endpoints are the gold standard. When a study claims benefit, ask how many participants, how long, whether outcomes were pre-registered or found after the fact, who funded it, and whether the effect size was clinically meaningful or merely statistically significant.
Step 3: Follow the money and the careers. Financial interests don’t invalidate research, but they reliably shift how results get communicated. Researchers with commercial interests in a space communicate more optimistically about it than independent researchers with no stake in the outcome — documented behavior across pharmaceutical, nutritional, and supplement research. Apply a skepticism premium to anyone communicating research with a financial stake in a positive conclusion. The right response isn’t dismissal — it’s requiring independent replication before committing real resources or health decisions to the finding.
Step 4: Assess the counterfactual honestly. When evaluating someone’s self-reported optimization results — Sinclair’s epigenetic markers, a colleague’s biomarker panel, anyone who claims to have “reversed” their biological age — ask what would be expected if the specific interventions were swapped out for equally consistent sleep, exercise, plant-forward diet, and stress management. The counterfactual stays invisible but matters. Plenty of people running complex supplement stacks are also making comprehensive lifestyle changes at the same time; crediting the supplements over the lifestyle shift requires a careful separation that’s rarely done honestly in personal testimonials.
Step 5: Run the risk-benefit calculation individually. Even interventions with incomplete evidence can carry favorable expected value if the downside is low and the upside meaningful. 500mg of NMN daily has a low risk profile and accumulating positive evidence — the risk-benefit supports it for many adults even without a definitive longevity trial behind it. A prescription drug with real side effects, taken on animal longevity data without physician oversight, is an entirely different calculation. Match the evidence bar to the stakes.
The Practical NAD+ Restoration Protocol
NAD+ supplementation is one of the most widely adopted pieces of Sinclair-inspired protocols, and it’s one where implementation detail matters more than most people assume. Getting the dose, timing, form, and synergistic factors right determines whether this intervention pays off or just burns money.
NMN vs. NR: Both reliably raise blood NAD+. NR has the longer human clinical trial history and is typically cheaper. NMN has more recent research support and may have superior uptake in certain tissues — muscle, liver — thanks to the SLCO2B1 transporter characterized in 2019. Both are defensible. Cost-conscious: NR runs roughly $30-50 a month. Closest to Sinclair’s own protocol: NMN.
Timing and co-factors: Taking NAD+ precursors in the morning lines up with the natural circadian peak of NAD+ biosynthesis and may improve efficacy. Taking them with fat and protein, the way Sinclair does with yogurt, may aid absorption, though the effect is modest and not a hard requirement. The bigger co-factor is magnesium: NAD+ synthesis runs through magnesium-dependent enzymatic steps, and magnesium deficiency — common on processed-food-heavy diets — can bottleneck the benefit of any NAD+ precursor downstream. Getting magnesium adequate — the glycinate form is the usual choice — before and during NAD+ supplementation is a practical upgrade.
CD38 inhibition as a complementary strategy: CD38 is an enzyme that consumes NAD+, and its expression rises with age and with senescent cell accumulation. Some researchers argue inhibiting CD38 matters as much as supplementing precursors, since raising NAD+ input while CD38 degrades it rapidly limits net retention. Natural CD38 inhibitors include apigenin (parsley, chamomile, celery) and quercetin, the same compound used in senolytic cycles. Eating apigenin-rich foods or taking quercetin as part of a senolytic cycle provides modest CD38 inhibitory benefit — a systems-level approach: supplement the precursor, reduce the degradation enzyme, support the cofactors that make synthesis efficient.
Applying the Information Theory of Aging in Practice
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map